|
| 利拉鲁肽的文献计量学分析 |
| Literature Analysis of Liraglutide |
| |
| DOI： |
| 中文关键词: 利拉鲁肽 文献计量学 科学引文牵引 中国知网 |
| 英文关键词:Liraglutide Bibliometrics analysis SCI CNKI |
| 基金项目: |
|
| 摘要点击次数: 982 |
| 全文下载次数: 1034 |
| 中文摘要: |
| 摘 要 目的：深入了解利拉鲁肽的研究概况，客观反映相关国家、机构和科学家在研究利拉鲁肽的领域中具备的科学能力和影响力。方法：以科学引文索引（SCI）数据库Web of Science为检索平台，以liraglutide or victoza or saxenda”为主题词进行检索，采用文献计量学的方法，分析以利拉鲁肽为主题的相关文献在国家/地区、机构、作者来源、出版物、年发文量、年引文量和引用排名前10名的情况。同时，以中国知网（CNKI）中的中国期刊全文数据库为检索平台，检索以“利拉鲁肽或诺和力”为主题词的所有中文文献并进行文献计量学的分析。时间跨度为1986年1月1日～2015年10月5日。结果：在Web of Science数据库中检索到文献1 596篇，发文量与引文数呈递增趋势，h index 为63；美国和丹麦的研究超过总数的一半以上总被引前10 位的SCI 文章有7篇为LEAD项目的试验结果，我国发表的SCI 文献为110篇；CNKI中收录的中文文章有348篇，10家机构中的9家为综合性的三级甲等医院，发文量最多的为解放军总医院。结论：关于利拉鲁肽的研究，是逐渐上升的趋势，仍是目前研究的热点。中国与国际前沿研究间存在着一定差距。 |
| 英文摘要: |
| ABSTRACT Objective:To investigate the situation of liraglutide study，and to reflect the science power and influence power of related countries，institutions and scientist. Methods:With Web of Science database of ISI Web of Knowledge as retrieval object，all literatures using“liraglutide or victoza or saxenda”as keyword were retrieved. By bibliometrics method, top 10 related literatures about personalized medicine were analyzed in the list of country/region, institution, source publication, annual number of publication, annual number of citation and citation ranking. Using CNKI database as retrieval object, Chinese literatures with“liraglutide or victoza”as keyword were retrieved and analyzed from January 1st 1986 to December 5th 2015. Results:1 596 information bits were retrieved from Web of Science database; the number of publication and citation increased progressively, and h index was 63; the number of publication from USA and Denmark accounted for more than half of the whole; there were 7 articles about Liraglutide Effect and Action in Diabetes(LEAD) among top 10 articles. The number of SCI articles written by Chinese scientists was 110; and 348 information bits were retrieved from CNKI. There were 9 comprehensive level 3 of first class hospitals among the 10 institutions, the most published papers was the people's liberation army general hospital. Conclusion:At present，liraglutide was still a hot spot. The research in China still lagged behind its international peers. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
